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Abstract: The radiolabeling of the natural octapeptide CCK8, derivatized with a cysteine residue (Cys-Gly-CCK8), by using
the metal fragment [99mTc(N)(PNP3)]2+ (PNP3 = N ,N-bis(dimethoxypropylphosphinoethyl)methoxyethylamine) is reported. The
[99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ complex was obtained according to two methods (one-step or two-step procedure) that gave
the desired compound in high yield. The complex is stable in aqueous solution and in phosphate buffer. In vitro challenge
experiments with an excess of cysteine and glutathione indicate that no transchelation reactions occur, confirming the high
thermodynamic stability and kinetic inertness of this compound. Stability studies carried out in human and mouse serum, as
well as in mouse liver homogenates, show that the radiolabeled compound remains intact for prolonged incubation at 37 °C.
Binding properties give Kd (19.0 ± 4.6 nmol/l) and Bmax (∼106 sites/cell) values in A431 cells overexpressing the CCK2-R.
In vivo evaluation of the compound shows rapid and specific targeting to CCK2-R, a fourfold higher accumulation compared to
nonreceptor expressing tumors. Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
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INTRODUCTION
Peptides are receptor-specific molecules that play an
important role not only in the diagnosis and therapy
of neoplastic diseases but also in the pathogenesis
of other diseases [1–3]. This fact has generated high
interest in the field of nuclear medicine and has
stimulated the development of several radiolabeling
procedures of these biomolecules with various radionu-
clides such as indium-111 (111In : t1/2 = 67.4 h; γ =
171; 245 keV) or iodine-131 (131I : t1/2 = 8.0 days; γ =
364 keV) either for imaging and/or therapy [4]. How-
ever, these radionuclides have less favorable imag-
ing characteristics owing to their high gamma ener-
gies. In this respect, technetium-99m (99mTc : t1/2 =
6.02 h; γ = 142 keV) represents, for diagnostic pur-
poses, the ideal choice for single-photon emission com-
puted tomography (SPECT).
Using this radionuclide, different peptide labeling
procedures are available from the literature [5,6].
Basically, in all reported procedures the target
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vector has to be: (i) derivatized with an appropri-
ate chelating system for the 99mTc; (ii) labeled with
high specific activity (low vector concentration) and
(iii) capable of retaining its physico-chemical proper-
ties and affinity toward the corresponding receptor
site. Moreover, for routine use the labeling proce-
dure should be performed preferentially in a single
step [5].
Recently, technetium mixed-ligand complexes dis-
playing characteristic substitution-inert metal frag-
ments ([Tc(CO)3]+ and [Tc(N)(PNP)]2+) have emerged as
alternative platforms in the design of potential 99mTc
‘target-specific’ radiopharmaceuticals [7–10]. In this
context, attempts to develop Tc-99m target-specific
agents using the [Tc(N)(PNP)]2+ synthon (PNP is an
aminodiphosphine) have recently been undertaken
[10–13]. As for the [Tc(CO)3]+ approach, one of the
major advantages of the [Tc(N)(PNP)]2+ technology was
the possibility to obtain well-defined complexes with
very high yields (>90%) depending on the co-ligand
[10–15]. Owing to its peculiar electronic structure, the
[Tc(N)(PNP)]2+ fragment exhibits a strong electrophilic
character and efficiently reacts with bifunctional lig-
ands (L) carrying π-donors as coordinating atoms (S,
O, N) to afford asymmetrical nitrido heterocomplexes of
the type [Tc(N)(L)(PNP)]0/+.
Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
212 AGOSTINI ET AL.
Naturally occurring bidentate ligands such as
cysteine display excellent coordinating properties
toward the [Tc(N)(PNP)]2+, providing a simple way
of incorporating short peptide chains into a nitrido
Tc-99m asymmetrical complex. Cysteine binds the
[Tc(N)(PNP)]2+ moiety either through the [NH2, S−] pair
or, alternatively, the [O−, S−] pair of donor atoms to
yield the corresponding mixed compound with high
specific activity (approximately 70 GBq/µmol). Thus
efficient bifunctional ligands can be easily obtained by
coupling the selected target vector to the carboxylic or
amino terminal group of a cysteine residue to give COO-
functionalized NH2, S-cysteine or N-functionalized O,
S-cysteine ligands, respectively [10]. Asymmetrical
[99mTc(N)(cys ∼)(PNP)]0/+ complexes, characterized by
remarkable in vitro and in vivo stability, were obtained
by reacting the [Tc(N)(PNP)]2+ metal fragment with the
bifunctional ligand (cys ∼) [13,16]. The overall charge
of the resulting mixed compound is dependent on the
pair of donor atoms of cysteine. A [NH2, S
−] chelating
system yields monocationic complexes, while neutral
complexes arise when cysteine coordinates through the
[O−, S−] pair [10].
We report here the first application of [Tc(N)(PNP)]2+
technology to the labeling of a small bioactive peptide. In
this study PNP3 (N ,N-bis(dimethoxypropylphosphino-
ethyl)methoxyethylamine) was selected as the amin-
odiphosphine ligand and CCK8 was chosen as carrier
bioactive peptide. This natural octapeptide is able to
recognize the CCK receptors (CCK1-R and CCK2-R).
Both receptors, localized in the cell membrane, belong
to the G-protein-coupled receptor (GPCR) superfam-
ily and are overexpressed in many malignant tumors.
CCK1-R is expressed rarely in tumors except in gas-
troenteropancreatic tumors (38%), meningiomas (30%)
and some neuroblastomas (19%). CCK2-R is found fre-
quently in medullary thyroid carcinomas (92%), small
cell lung cancer (57%), astrocytomas (65%) and stromal
ovarian tumors (100%), while it is found occasionally in
gastroenteropancreatic tumors and breast endometrial
and ovarian adenocarcinomas [17–20].
In the past years the receptor interaction with the
CCK peptide conjugates, modified on N-terminal-aa
sequence with chelating groups to coordinate sev-
eral radioactive metals such as In, Y or Re, was
chemically and biologically investigated by several
researchers [21–28]. In this context, the search for
a 99mTc-based radiotracer for targeted tumor imag-
ing has involved hydrazino-nicotinamide (HYNIC)/co-
ligand, tricarbonyl/N2O, N4 derivatized CCK or gastrin
analogs [29–31].
All conjugates preserve their receptor affinity, but
the stability and the biodistribution in vivo are highly
dependent on the chelating moiety. These results
stimulate to improve the inertness of the metal
complexes and the biodistribution properties. Some
issues can benefit from further studies; therefore,
it is worthwhile to assess the efficacies of different
compounds and different labeling approaches.
Here, we describe the preparation and the chromato-
graphic characterization of the [99mTc(N)(NS-Cys-Gly-
CCK8)(PNP3)]+ peptide conjugate complex. Its in vitro
stability was investigated in phosphate buffer solu-
tion (PBS), cysteine and glutathione solutions, as well
as in human serum, mouse serum and mouse liver
homogenates. Receptor binding specificity and affinity
were evaluated in a cell culture system of CCK2-R over-
expression. Preliminary in vivo receptor targeting and
biodistribution studies were performed in nude mice
bearing xenografts of A431-CCK2-R cells and A431
control cells.
MATERIALS AND METHODS
General
All chemicals and reagents were purchased from Sigma Aldrich
(Milan, Italy). All solvents were of reagent grade and were used
without further purification. The aminodiphosphine ligand
N ,N-bis(dimethoxypropylphosphinoethyl)methoxyethylamine
[PNP3 = (CH3OC3H6)2P(CH2)2N(C2H4OCH3) (CH2)2P(C3H6
OCH3)2] was purchased from Argus Chemicals (Prato, Italy).
Owing to the tendency of the diphosphine ligands to oxidize, all
the solvents used in the reactions with PNP3 were previously
degassed to remove traces of dissolved dioxygen. Fmoc-amino
acids and the other reagents for peptide synthesis were pur-
chased from INBIOS (Pozzuoli, Italy).
Technetium-99m as Na99mTcO4 was eluted from a
99Mo/99mTc generator provided by Nycomed Amersham-Sorin
(Saluggia, Italy).
Sep-Pak RP-C18 and OASIS HLB extraction cartridges were
purchased from Waters Corporation (Milford, MA, USA).
Analysis
TLC (SiO2 F254S and C18 F254S, Merck) and HPLC analyses
were used to evaluate the radiochemical yield (RCY) and the
stability as radiochemical purity (RCP) of the compounds. The
radioactivity on TLC plates was detected and measured using
a Cyclone instrument equipped with a phosphorus imaging
screen and the OptiQuant image analysis software (Packard,
Meridian, CT). HPLC was performed on a Beckman System
Gold instrument equipped with a programmable solvent Model
126, a scanning detector Module 166 (λ = 215 µm) and a
radioisotope detector Model 3200 Bioscan.
HPLC analysis was performed with a reverse-phase Beck-
man C18 precolumn (5 µm, 4.6 × 45 mm) and a Beck-
man C18 column (5 µm, 4.6 × 250 mm). The flow rate was
1 ml/min. The results are summarized in Table 1 and com-
pared with the chromatographic data of the analogous
(syn/anti) [99mTc(N)(NS-Cys-OEt)(PNP3)]+ (where NS-Cys-OEt
was L-cysteine ethylester) compound, prepared as previously
described [9,10].
Peptide Synthesis
The NS-Cys-Gly-CCK8 peptide was obtained by solid-phase
peptide synthesis, performed under standard conditions using
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Table 1 Chromatographic data of 99mTc-complexes
Complex TLC RF C18 TLC RF SiO2 HPLC RT (min) %RCY a + b
a − [99mTcN(NS-Cys-OEt)(PNP3)]+ a0.33 — d26.03 91.37
b − [99mTcN(NS-Cys-OEt)(PNP3)]+ a0.21 — d29.03
a − [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ b0.65; c0.85 a0.67 d25.45; e29.89 90.0
b − [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ b0.65; c0.85 a0.61 d25.45; e29.89
TLC: C18: a MeCN/Et3N 0.01 M (pH 3, H3PO4 1 M) (60/40); b Sal/MeOH/THF/HAc(g), (2/8/1/1); c MeOH/MeCN/THF/HAc(g)
(3/3/2/2). SiO2: 1EtOH/CHCl3/Tol/NH4Ac (0.5 M) (6/2/0.5/1.5).
HPLC: A = NEt3 0.01 M pH 3 for H3PO4 1 M, B = CH3CN; d gradient: 0–5 min, B, 0%; 5–15 min, B 30%; 15–20 min, B 45%;
20–35 min, B, 45%; 35–37 min, B, 0%. e gradient: 0–5 min, B, 0%; 5–15 min, B 30%; 15–20 min, B, 39%; 20–40 min, B, 39%;
40–42 min, B, 0%.
the Fmoc strategy. The amino acid sequence of the Cys-Gly-
CCK8 peptide, with the amidated C-terminus as in the natural
peptide, was Cys24-Gly25-Asp26Tyr27Met28Gly29Trp30Met31
Asp32Phe33NH2, according to the numbering of CCK-33.
The fully automated peptide synthesizer Applied Biosys-
tem model ABI 433 was used, adopting the 0.250 mmol
scale. The Rink-amide 4-methylbenzhydrylamine (MBHA)
resin, loading 0.5 mmol/g, was used. Double couplings
were performed, adding four equivalents of protected
amino acids activated by 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium-hexafluorophosphate (HBTU) and HOBt,
and eight equivalents of DIPEA in N-methylpyrrolidone (NMP);
the stirring time was 60 min for each coupling. For depro-
tection and cleavage, the fully protected Cys-Gly-CCK8 pep-
tide resin was treated with TFA containing tri-isopropylsilane
(1.0%), ethanedithiol (2.5%) and water (2.5%). The crude pep-
tide was precipitated at 0 °C by adding diethyl ether dropwise.
Purification of the crude mixtures was carried out by RP-HPLC.
Analytical RP-HPLC was carried out on a Shimadzu 10ADvp
instrument using a Vydac C18 column, 4.6–250 mm, eluted
with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) with lin-
ear gradient from 5 to 65% B over 20 min at 1 ml/min flow
rate. Preparative RP-HPLC was carried out on a Shimadzu 8A
instrument equipped with a UV–vis Shimadzu detector using
a Vydac C18 column, 22–250 mm, with the same eluents
as used on the analytical scale and a gradient from 20 min at
25 ml/min flow rate. Rt was 19.96 min. Mass spectra recorded
on a MALDI-TOF Voyager-DE (PerSeptive Biosystems) sys-
tem confirmed the product identity: Mw (NS-Cys-Gly-CCK8) =
1220.
Preparation of [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+
Method 1 (two-step procedure): Na99mTcO4(0.5 ml, 50.0 MBq-
3.0 GBq) was added to a vial containing succinic dihydrazide
(SDH) (5.0 mg), SnCl2 (0.1 mg suspended in 0.1 ml of saline)
and ethanol (0.5 ml). The vial was kept at room temperature for
30 min giving a mixture of 99mTc–nitrido precursors [99mTc ≡
N]2+. Then the PNP3 ligand (1.0 mg dissolved in 0.1 ml of
EtOH) and NS-Cys-Gly-CCK8 (0.10 mg suspended in 0.250 ml
of phosphate buffer 0.1 M pH 7.4) were simultaneously added,
and the reaction mixture was heated at 80 °C for 60 min.
The pH of the reaction mixture, measured at the end of
the reaction, was 7. RCY as determined by TLC and HPLC
chromatography was 90.0%.
Method 2 (one-step procedure): Na99mTcO4 (0.5 ml, 50.0
MBq-3 GBq) was added to a vial containing SDH (5.0 mg),
SnCl2 (0.1 mg suspended in 0.1 ml of saline), ethanol
(0.5 ml), NS-Cys-Gly-CCK8 (0.1 mg suspended in 0.250 ml
of phosphate buffer 0.1 M pH 7.4) and PNP3 (1 mg dissolved
in 0,1 ml of EtOH). RCY determined by TLC and HPLC, after
60 min at 80 °C, was 90.9%.
The [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ isolated by HPLC
was concentrated on a Sep pack C18 column rinsed with H2O
(10 ml) and eluted using a mixture of EtOH/phosphate buffer
0.2 M, pH 7.4, 80/20 (1 × 0.25 ml, 1 × 0.75 ml). The second
fraction containing all the activity was utilized for in vitro and
in vivo studies. After purification, the RCP evaluated by TLC
and HPLC was >95%.
Radiolabeling Efficiency of NS-Cys-Gly-CCK8 Ligand
The radiolabeling efficiency of the NS-Cys-Gly-CCK8 ligand
was determined following the standardized labeling condition
reported in method 2.
The amount of PNP3 was fixed at 1 mg (2.06 × 10−3 mmol),
while the concentration of the NS-Cys-Gly-CCK8 ligand
was progressively decreased in the range 200 µg (1.64 ×
10−4 mmol) to 5 µg (4.08 × 10−6 mmol). The mixture was
incubated at different temperatures (100, 80, 50 °C and RT)
for 60 min. The RCY at 15, 30 and 60 min was determined by
TLC and HPLC.
In vitro Studies
Cysteine (Cys) and glutathione (GSH) challenge. Challenge
experiments were carried out on the purified complex using
an excess of Cys or GSH. An aliquot (50 µl) of an aqueous
stock solution of cysteine hydrochloride (10 mM or 1 mM)
was added to a propylene test tube containing phosphate
buffer (250 µl, 0.2 M; pH 7.4), water (100 µl) and the
[99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ complex (100 µl). The
mixture was vortexed and incubated at 37 °C for 24 h. A
control reaction containing an equal volume of water, instead
of cysteine hydrochloride, was studied in parallel. At 30 min, 1,
2, 3 and 24 h, aliquots of the reaction mixture were withdrawn
and analyzed by TLC and HPLC. A similar procedure was
applied using GSH (50 µL, 10 mM) as the challenge ligand. The
experiments were performed in duplicate.
In vitro stability. The in vitro stability of the complex was
evaluated by monitoring the RCP at different time points using
the following procedures: in a propylene test tube, 50 µl of
purified Tc-99m compound was added to: (a) 950 µl of saline,
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(b) 450 µl of human serum, (c) 450 µl of mouse serum and
(d) 450 µl of homogenate of mouse liver. The resulting mixture
was incubated at 37 °C for 24 h.
At 15 min, 1, 2, 3 and 24 h, aliquots (50 µl) of each solution
were withdrawn, and diluted with 950 µl of phosphate buffer
(0.02 M, pH 7.4).
One hundred microlitres of the sample a, b and c
were withdrawn and directly analyzed by HPLC using
the following elution conditions: reverse-phase Symmetry
300 C4 precolumn (5 µm, 3.9 × 20 mm) and a reverse-phase
Symmetry 300 C4 column (5 µm, 4.6 × 150 mm). Solvents:
A = DMGA (0.05 M pH 8, for NaOH 0.1 M; DMGA = 3,3
dimethylglutaric acid), B = CH3CN; Gradient: 0 min, B, 25%;
0–25 min, B, 33%; 25–27 min, B, 25%. Flow rate 1 ml/min.
At the same time, the sample d was treated using an OASIS
HLB extraction cartridge before HPLC injection. The sample
was loaded on the cartridge, conditioned with MeOH (1 ml),
equilibrated with water (1 ml) and rinsed with MeOH 5% (3 ml).
The activity was eluted with a mixture of EtOH/phosphate
buffer 0.2 M, pH 7.4, 80/20 (1 ml). Eighty percent of the initial
activity was collected in the elution fraction and analyzed by
TLC and HPLC.
The experiments were performed in duplicate.
Binding experiments. Saturation binding experiments were
performed on A431 cells overexpressing the CCK2-R following
the procedure previously described [27]. Briefly, the cells were
plated at a density of 1–200 000 cells/well in 12 multiwell
plates 2–3 days prior to the experiments. Duplicate wells were
incubated with serial dilutions of the labeled compound in the
culture medium at 4 °C. Bound radioactivity was recovered
by trypsinizing the cells after two rapid washes in ice-
cold PBS following 1 h incubation and measured by gamma
counting. Binding curves were generated after normalizing
for the number of cells and subtracting nonspecific binding
using the Kaleidagraph software (Abelbeck Software, Version
3.5, distributed by Synergy Software, Reading, PA). The
dissociation constant (Kd) and the apparent number of binding
sites per cell (Bmax) were derived by fitting to a standard
saturation binding model as described [27].
Biodistribution Studies
Xenografts of A-431 cells overexpressing the CCK2-R and
control cells were generated in the opposite flanks of 6-
week-old CD-1 nude mice (weight 17–23 g). The tumors
were allowed to grow for 10–14 days following subcu-
taneous injection. The tissue and tumor distribution of
[99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ was determined 1 h after
injecting ∼50 µCi/mouse of labeled peptide in the lateral tail
vein in five animals. Blood, lung, liver, spleen, kidney, stom-
ach, gastrointestinal tract, muscle and xenograft samples were
weighed, and the radioactivity determined by gamma count-
ing. Dilutions of the injected compound were simultaneously
counted for accurate determination of the injected dose. The
relative amount of radioactivity in the organs was calculated
and expressed as percentage of the injected dose/gram of
tissue (%ID/g), normalized to a 20-g mouse.
RESULTS AND DISCUSSION
Evidence on the CCK-2/gastrin-R expression in several
malignant tumors has provided the molecular basis
for the development of radiolabeled CCK and gastrin
analogs for targeted tumor imaging and radionuclide
therapy [17–20]. Several research groups have been
actively engaged in this effort using either CCK or
gastrin motifs [21–28]. In this contest, the search for a
99mTc-based radiotracer for targeted tumor imaging has
begun with recent studies involving various labeling
approaches with different chelating systems derivatized
with CCK or gastrin analogs [29–31].
Recently, we have described the synthesis of a new
class of asymmetrical nitrido complexes, based on the
chemical properties of the substitution labile complex
[Tc(N)X2(PNP)], which represents an interesting oppor-
tunity in designing receptor-specific Tc-99m agents
[11–13]. The effective applicability of this method to the
labeling of pharmacophore groups has been reported
recently [13]. Using the avidin–biotin system as a
model, a series of 99mTc-nitrido complexes containing
functionalized biotin ligands were prepared and their
biological profiles determined. In these compounds, the
steric and the electronic influence of the Tc-carrying
complex on the biotin–avidin receptor interaction was
evaluated, evidencing that a careful selection of the
spacer (at least a five-terms spacer) may prevent the
perturbation of the pharmacophore group operated by
the inorganic moiety, thereby leaving the biomolecule
free to interact with the receptor.
On the basis of these results, we decided to extend
the applicability of [Tc(N)(PNP3)]2+ technology to the
preparation of target-specific radiolabeled peptides.
Among several biologically active forms of CCK, the
nonsulfated octapeptide CCK8 was selected as the tar-
get vector. The peptide was combined through the
terminal carboxylic group of the cysteine residue, to
afford a COO-functionalised NH2, S-cysteine ligand. A
glycine residue was introduced as the spacer group
between the chelating agent and the biologically active
peptide. The choice of cysteine position on the peptide
skeleton sequence was based on previous results of
molecular modeling studies (quantum mechanics and
molecular mechanics) [32] which indicated that modi-
fications on the N-terminal side of CCK8 obtained by
introducing chelating moieties and their metal com-
plexes should not affect the interaction with CCK recep-
tors and should allow the CCK8 peptide to adopt the
appropriate conformation for receptor binding. In addi-
tion, molecular mechanics calculations showed that the
stabilization involved in the conjugate–CCK8/CCK1-R
complex formation was about of the same order of mag-
nitude as the CCK8/CCK1-R complex formation [32].
The NS-Cys-Gly-CCK8 peptide was synthesized
according to the standard Fmoc chemistry procedure.
The ligand was purified by HPLC and the identity estab-
lished by mass spectroscopy.
Application of the ‘metal fragment’ approach is out-
lined as follows: the bifunctional ligand was reacted
with the metal fragment to afford the monopositive
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[Tc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ asymmetrical com-
plex. The resulting 99mTc(N) mixed compound has been
evaluated with regard to the following criteria: (i) ease
of radiosynthesis and labeling efficiency; (ii) stabil-
ity toward transchelation with Cys and GSH; and
(iii) stability toward degradation with human serum,
mouse serum and mouse liver homogenates. The capa-
bility of the native peptide sequence to preserve the
biological properties was investigated both in vitro and
in vivo. In particular, A431 cells overexpressing the
CCK2-R were used to evaluate the in vitro affinity of
the compound. Nude mice bearing control and CCK2-
R-overexpressing A431 xenografts were used as the
in vivo model.
Preparation of [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+
The labeling procedures employed in preparation of the
monocationic [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ are
sketched in Scheme 1.
The preparation of the asymmetrical complex was
conducted following two different methods. A two-
step procedure (method 1) involved the preliminary
production of a mixture of 99mTc-nitrido precursors, all
containing the [Tc ≡ N]2+ core, through the reduction
of pertechnetate with tin(II) chloride in the presence
of SDH as donor of the nitrido nitrogen atom. In the
second step, the diphosphine and the bidentate NS-
Cys-Gly-CCK8 ligand were simultaneously added to the
reaction vial to afford, after 30 min at 80 °C, the final
mixed compound in high yield.
Alternatively, a one-step procedure (method 2) can be
used to obtain the final asymmetrical compound. This
procedure was carried out through the addition of a
fresh pertechnetate solution to the vial containing the
following reagents: SnCl2, SDH, PNP3 and NS-Cys-Gly-
CCK8.
The [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ complex
exhibited the same chromatographic profile as that
obtained by method 1 (Figure 1).
Interestingly, both procedures gave almost the
same final RCYs for the asymmetrical product, and
conversion to the corresponding symmetrical complexes
comprising two identical bidentate ligands was never
detected.
The high yield of the final mixed compound obtained
in the one-pot procedure proves that the formation of
the [Tc ≡ N]2+ core was accompanied with the rapid
coordination of PNP3 to form the [99mTc(N)(PNP3)]2+
metal fragment. These results demonstrated that
the PNP ligand plays a fundamental role both in
stabilizing the [99mTcV(N)]2+ core and in promoting
the reactivity of the intermediate complex containing
the [99mTc(N)(PNP)]2+ moiety, which immediately and
Na TcO4 + SnCl2 + SDH [TcN]2+int.
PNP3/ NS-Cys-Gly-CCK8
60 min 80°C
30 min RT
Tc
P
P S
N
N
R'
R
R
R R
syn/anti
NH
C
OH2N
C
CCK8
O
Na TcO4 + SnCl2 + SDH + PNP3 +NS-Cys-Gly-CCK8
Method 1
Method 2
60 min 80°C
R = -CH2CH2CH2OCH3
R' = -CH2CH2OCH3
Scheme 1 The labeling procedures employed in preparation of the monocationic [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ complex.
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Figure 1 HPLC comparison of the (syn/anti) [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ complex prepared (A) by method 1(two-step
reaction), 60 min 80 °C and (B) by method 2 (one-step reaction), 60 min 80 °C.
efficiently reacted with the bidentate ligand to afford
the final compound.
TLC and HPLC data of the complexes and their RCY
are summarized in Table 1.
TLC techniques revealed, analogously to what was
observed for the [99mTc(N)(NS-Cys-OEt)(PNP3)]+ com-
plex [10], the existence of two different compounds in
about the ratio 60 : 40, as the syn/anti isomeric forms of
the asymmetrical [99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+
complex, depending on the orientation of the COO-
substituted cysteine pendant group with respect to the
central Tc ≡ N-terminal core. Unfortunately, it was not
possible by HPLC to achieve isomeric resolution under
a wide range of chromatographic conditions. There-
fore, the mixture of the two isomeric forms was directly
utilized for in vitro and in vivo studies.
Labeling Efficiency of the NS-Cys-Gly-CCK8 Ligand
For a receptor-based peptide radiopharmaceutical, the
use of a large amount of the bifunctional chelating agent
(BFCA)-peptide may result in receptor site saturation,
blocking the docking of the 99mTc-labeled BFCA-
conjugate, as well as in unwanted pharmacological
side effects. Consequently, the concentration of the
BFCA-conjugate in each preparation has to be very
low, usually in the 10−5 − 10−6 M range [6]. An
estimation of the labeling efficiency of the N-cysteine-
modified CCK analog was reported. In particular,
we investigated the influence of concentration of
the NS-Cys-Gly-CCK8 ligand on the RCY of the
[99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ heterocomplex. In
detail, following the one-step procedure (method 2), the
bidentate ligand was labeled at different concentrations
under standardized conditions – concentration of PNP3
ligand (1.0 mg), temperature (100, 80, 50 °C and RT)
and reaction times (15, 30 and 60 min). The dependence
of the RCY of the heterocomplex formation on the NS-
Cys-Gly-CCK8 concentration (200–5 µg) is reported in
Table 2.
Data revealed that the highest RCY was achieved
with an amount of NS-Cys-Gly-CCK8 in the range
of 200–50 µg, corresponding to a molar amount in
the range 1.13 × 10−4 − 2.81 × 10−5 M. In this concen-
tration interval, no significant variation of the %RCY
was observed by increasing the temperature to 100 °C.
Shorter reaction time (15 min) and lower temperature
(50 °C and RT) reduced the RCY.
In vitro Studies
The labeled product was stable in the saline and
phosphate buffer (0.2 M; pH 7.4) for 24 h, and it was
found to be highly inert toward transchelation by an
excess of free cysteine or glutathione, confirming the
high thermodynamic stability and kinetic inertness of
this compound.
The in vitro stability of the compound was evaluated
after incubation with human serum, mouse serum
and homogenate of mouse liver at 37 °C for 24 h. The
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Table 2 Effect of the amount of ligands and temperature
on the %RCY formation of the complex [99mTc(N)(NS-Cys
-Gly-CCK8)(PNP3)]+. The experiments were performed in
triplicate
NS-Cys-Gly-CCK8 Temperature Time %RCY
(°C) (min)
(µg) (mmol)
200 1.6 × 10−4 80 60 91.0 ± 3.4
100 8.2 × 10−5 80 60 90.0 ± 2.01
50 4.1 × 10−5 80 60 86.6 ± 1.09
25 2.1 × 10−5 80 60 75.6 ± 2.00
10 8.2 × 10−6 80 60 63.1 ± 2.89
5 4.1 × 10−6 80 60 30.6 ± 1.99
200 1.6 × 10−4 80 30 87.4 ± 1.91
100 8.2 × 10−5 80 30 86.1 ± 2.01
50 4.1 × 10−5 80 30 77.5 ± 1.09
25 2.1 × 10−5 80 30 63.1 ± 1.00
10 8.2 × 10−6 80 30 49.8 ± 2.89
5 4.1 × 10−6 80 30 21.6 ± 3.99
200 1.6 × 10−4 80 15 76.3 ± 6.40
100 8.2 × 10−5 80 15 75.2 ± 5.00
50 4.1 × 10−5 80 15 64.4 ± 3.09
200 1.6 × 10−4 100 60 92.0 ± 4.90
100 8.2 × 10−5 100 60 89.9 ± 3.21
50 4.1 × 10−5 100 60 83.6 ± 2.09
200 1.6 × 10−4 50 60 71.0 ± 1.4
100 8.2 × 10−5 50 60 69.0 ± 1.01
50 4.1 × 10−5 50 60 66.6 ± 2.09
200 1.6 × 10−4 RT 60 62.1 ± 3.6
100 8.2 × 10−5 RT 60 53.0 ± 1.98
50 4.1 × 10−5 RT 60 39.1 ± 4.20
complex was found to be stable in all conditions within
the first 3 h (Figure 2). At 24 h, 80% of the activity
was associated with the peptide after incubation in
human serum, and about 50% after incubation in
mouse serum. This fact suggests that the complex was
stable to the enzymatic actions.
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Figure 2 In vitro stability studies of the (syn/anti) [99mTc(N)
(NS-Cys-Gly-CCK8)(PNP3)]+ complex.
Cell Binding
Experiments were performed at 4 °C to block receptor
internalization and thereby to measure only the ligand-
receptor interaction.
[99mTc(N)(NS-Cys-Gly-CCK8)(PNP3)]+ showed high
specific binding to A431-CCK2-R cells, with the typi-
cal saturation curve (Figure 3). The apparent Kd for the
receptor was estimated to be 19.0 ± 4.6 nmol/l (mean
± SE), and the number of binding sites was in the order
of 106 per cell.
The level of nonspecific binding, evaluated by
incubation of the complex with nonreceptor expressing
cells or with receptor expressing cells in presence of
100–fold excess of unlabeled peptide, was very low.
These values were similar to those found in other CCK8
derivatives previously described [27].
Biodistribution Experiments
The preliminary tissue distribution studies of the
radiolabeled peptide evaluated in nude mice at 1 h p.i.
are reported in Figure 4. The complex exhibits rapid and
specific uptake in the CCK2-R positive A431 xenografts
compared to the receptor-negative tumor, with a target-
to-nontarget ratio (receptor positive/receptor-negative
tumor) of 4 : 1. The activity was rapidly cleared from
blood and normal tissues (lungs, spleen and muscle).
Relatively high concentrations of the compound were
also observed in liver and kidneys. Clearance of the
unbound radioactivity appeared to be mainly through
the hepato-biliary system, as most activity at 1 h was
found in the intestinal tract.
A number of other CCK-R binding peptides, labeled
with different approaches, have been evaluated [22–29].
Receptor-specific targeting has been easily achieved,
and much of the development efforts has focused
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Figure 3 Receptor binding of the (syn/anti) [99mTc(N)(NS-
Cys-Gly-CCK8)(PNP3)]+ on A431-CCK2-R cells at 4 °C. The
cell line showed saturable binding of the peptide conjugate
with equivalent Kd = 19.0 ± 4.6 nmol/l. The Bmax value was
7.7 × 105 per cell.
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Figure 4 Biodistribution data at 1 h after intravenous
injection. Organ-associated radioactivity was expressed as the
%ID per gram of tissue normalized to a 20-g mouse.
on reducing nontarget tissue accumulation. Most
compounds described appear to be preferentially
cleared through the urinary system, although in some
cases high retention level in the kidneys for prolonged
periods can be observed. This drawback may sometimes
require corrective measures such as co-injection of
competing compounds to reduce kidney uptake [33].
The high intestinal activity of [99mTc(N)(NS-Cys-
Gly-CCK8)(PNP3)]+ is indeed less desirable; however,
the remarkably rapid clearance with the resulting low
liver as well as kidney retention warrants further devel-
opment of such labeling schemes in order to improve
the overall distribution properties of compounds labeled
with this approach. In order to promote the renal excre-
tion pathway, more hydrophilic labeling systems should
be used.
CONCLUSIONS
Stable 99mTc(N) technetium complex incorporating a
bioactive peptide was successfully obtained in high
yield through the application of the labeling procedure
based on [99mTc(N)(PNP)]2+ technology. The mixed
compound was efficiently prepared using a simple one-
step procedure, which met the basic requirements for
the safe and rapid synthesis of a pure radiochemical
agent.
Despite the linkage with the sterically demanding
[99mTc(N)(PNP3)]2+ molecular fragment, the labeling
procedure did not modify the receptor binding affinity
of the peptide. Actually, the binding constant to CCK2
receptors was in the same order as other peptide
radioisotope conjugates and was found to be adequate
for further evaluation. In vivo studies showed the
capability of the compound to target tumor cells.
These results are promising, but the pharmacokinet-
ics properties of the compound need to be improved.
Therefore, in view of the application of this
system in nuclear imaging, modification of the
hydrophilic/lipophilic properties of this compound will
be necessary to reduce its intestinal accumulation and
to increase its renal clearance as well as its CCK2-R
positive A431 xenografts uptake. Modification of the
complex can be achieved by increasing the hydrophilic
properties of the [Tc(N)(PNP)]2+ moiety through the
introduction of more hydrophilic or easily metabolizable
groups on the two phosphorus atoms, or alternatively,
by introducing an appropriate linker group between
the peptide and the BFCS capable of modulating the
hydrophilic or lipophilic properties of the final hetero-
complex.
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